Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test (CMTNCMB)

University of Chinese Academy Sciences

Status: Unknown

Conditions: Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer

Treatments: Combination Product: neoadjuvant chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT04264468

CMTNCMB

Details and patient eligibility

About

This study prospectively included 150 breast cancer patients (30 patients in the first stage and 120 patients in the second stage) who were treated with the commonly used neoadjuvant chemotherapy recommended by NCCN, received surgical treatment after neoadjuvant chemotherapy, and evaluated the efficacy according to the surgical pathological response.Based on the technical analysis of Mammaprint in patients with pathologic complete response (pCR), partial response and no response, we analyzed the characteristic genes related to breast cancer in tumor tissues and evaluated the accuracy and sensitivity of Mammaprint test in the efficacy of neoadjuvant chemotherapy.A new model for predicting NCT effect of breast cancer with combined risk genes and clinical parameters was established based on the clinical characteristic parameters of patients to study the accuracy and sensitivity of Mammaprint monitoring for prognosis determination of breast cancer patients.

Enrollment: 150 estimated patients

Sex: Female

Ages: 25 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically confirmed new breast cancer (invasive cancer)
• Clinical stage II-III
• women
• Aged 25-80
• At least 6 months of follow-up data, clinical diagnosis and treatment information and personal information available for follow-up are complete
• Complete biological samples required for the study: fresh/frozen tissues/white tablets/wax blocks meeting the requirements of the experiment (before neoadjuvant chemotherapy)
• Tumor markers and imaging data were complete
• Neoadjuvant chemotherapy is commonly recommended by the standard NCCN guidelines

Exclusion criteria

• Subjects refuse to participate
• First diagnosis of stage I or IV breast cancer
• Pathological diagnosis of concurrent (or previous) other malignant tumors
• Prehistory breast cancer
• Younger than 25 or older than 80
• Clinical diagnosis and treatment information or biological samples required by the research institute do not meet the needs of the experiment

Trial design

150 participants in 1 patient group

response group and the non-response group

Description:

Received neoadjuvant chemotherapy according to the routine clinical diagnosis and treatment, and evaluated the clinical efficacy once every two cycles of chemotherapy. According to the clinical efficacy, the patients were divided into the neoadjuvant chemotherapy response group and the non-response group (evaluation standard RECIST1.1).

Treatment:

Combination Product: neoadjuvant chemotherapy